RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) yesterday and set a price target of $24.00. The company’s shares closed yesterday at $14.49.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and uniQure. According to TipRanks, Issi has an average return of -18.3% and a 28.73% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lexeo Therapeutics, Inc. with a $22.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $22.33 and a one-year low of $9.00. Currently, Lexeo Therapeutics, Inc. has an average volume of 95.67K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lexeo Therapeutics, Inc. (LXEO) Company Description:
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More on LXEO:
- Lexeo Therapeutics’ Strategic $95M Share Placement and Financial Update
- Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
- 3 Best Stocks to Buy Now, 2/12/2024, According to Top Analysts
- Lexeo Therapeutics Bolsters Leadership with Key Hires
